Business Context and Reporting Period
This Form 8-K Current Report was filed by Bausch Health Companies Inc. on July 15, 2024. The filing primarily addresses Item 5.02 regarding the appointment of a new Chief Financial Officer and the retention of the interim CFO, as well as Item 7.01 regarding Regulation FD disclosure.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- New CFO Base Salary: $700,000 annually.
- New CFO Target Bonus: 60% of base salary.
- New CFO 2025 Equity Target: Approximately $3,000,000.
- New CFO Sign-On Cash: $300,000.
- New CFO Sign-On Equity: $3,500,000 (split 50/50 between time-based and performance-based RSUs).
- Interim CFO Retention Award: $350,000 in time-based RSUs.
- Interim CFO Stipend Extension: $5,000 bi-weekly through September 30, 2024.
Material Changes
The primary material change is the leadership transition in the finance function:
- Appointment: Jean-Jacques Charhon appointed as Executive Vice President and Chief Financial Officer, effective August 19, 2024.
- Role Change: John S. Barresi will cease acting as interim CFO and revert to Senior Vice President, Controller, and Chief Accounting Officer.
- Compensation Structure: Implementation of a new three-year employment agreement for Mr. Charhon with specific severance and clawback provisions, and a retention grant for Mr. Barresi.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. Key contractual terms and contingencies include:
- Clawback Provision: Mr. Charhon must repay the after-tax amount of his $300,000 sign-on bonus if he voluntarily resigns without "good reason" or is terminated for "cause" within the first two years.
- Severance Terms: Mr. Charhon is entitled to 1x salary plus target bonus upon termination without cause (increasing to 1.5x if before Dec 31, 2024, or 2x in a change of control scenario), plus pro-rata bonus and acceleration of sign-on RSUs.
- Retention Vesting: Mr. Barresi's $350,000 retention award vests in three equal annual installments, with accelerated vesting provisions for death, disability, or involuntary termination.
- Restrictions: Mr. Charhon is subject to non-compete, non-solicit, non-disparagement, and confidentiality restrictions.
Investor Verification Checklist
- Verify the effective start date of August 19, 2024, for the new CFO.
- Confirm the total potential cash and equity value of the new CFO's compensation package ($700k salary + $420k target bonus + $3M equity + $300k sign-on cash + $3.5M sign-on equity).
- Review the specific definitions of "cause" and "good reason" in the full Employment Agreement (to be filed as an exhibit to the Q3 2024 10-Q) to understand severance triggers.
- Monitor the vesting schedule of the $350,000 retention award granted to the departing interim CFO.